Patent filed for HemoBioTech's novel chemically modified hemoglobin for treatment of blood loss

By Lisa Kerner

Erie, Pa., May 18 - HemoBioTech, Inc. said that Texas Tech University filed a patent application for HemoTech, a potential blood substitute, describing its use and mechanism of action for induction of erythropoiesis (red blood cell production) as a treatment for blood loss.

"There is a strong interest in new agents which increase the level of red blood cells in patients, chairman and chief executive officer Arthur P. Bollon said in a company news release.

"The development of a blood substitute that not only carries oxygen, but also increases the level of red blood cells, could have broad applications in medicine, especially trauma, elective surgery, acute anemia, cancer and heart disease."

Dallas-based HemoBioTech is engaged in the commercial development of HemoTech, which is exclusively licensed from Texas Tech University Health Sciences Center.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.